Violet Pharmaceuticals advances first-in-class mRNA therapies for metastatic cancer, designed to enhance immunotherapy effectiveness by increasing antigen presentation and turning immune-resistant "cold" tumors into more responsive "hot" tumors. The company operates as a biotech spin-off focused on translating patented cancer biology research into therapeutic assets for oncology applications.